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Abstract
Background: St. John's wort (SJW), used to treat depression, is popular in the USA, Canada, and
parts of Europe. However, there are documented interactions between SJW and prescription
medications including warfarin, cyclosporine, indinavir, and oral contraceptives. One source of
information about these safety considerations is the product label. The aim of this study was to
evaluate the clinically relevant safety information included on labeling in a nationally representative
sample of SJW products from the USA.
Methods:  Eight clinically relevant safety issues were identified: drug interactions (SJW-HIV
medications, SJW-immunosupressants, SJW-oral contraceptives, and SJW-warfarin),
contraindications (bipolar disorder), therapeutic duplication (antidepressants), and general
considerations (phototoxicity and advice to consult a healthcare professional (HCP)). A list of SJW
products was identified to assess their labels. Percentages and totals were used to present findings.
Results: Of the seventy-four products evaluated, no product label provided information for all 8
evaluation criteria. Three products (4.1%) provided information on 7 of the 8 criteria. Four
products provided no safety information whatsoever. Percentage of products with label
information was: SJW-HIV (8.1%), SJW-immunosupressants (5.4%), SJW-OCPs (8.1%), SJW-
warfarin (5.4%), bipolar (1.4%), antidepressants (23.0%), phototoxicity (51.4%), and consult HCP
(87.8%). Other safety-related information on labels included warnings about pregnancy (74.3%),
lactation (64.9%), discontinue if adverse reaction (23.0%), and not for use in patients under 18 years
old (13.5%). The average number of a priori safety issues included on a product label was 1.91 (range
0–8) for 23.9% completeness.
Conclusion: The vast majority of SJW products fail to adequately address clinically relevant safety
issues on their labeling. A few products do provide an acceptable amount of information on
clinically relevant safety issues which could enhance the quality of counseling by HCPs and health
store clerks. HCPs and consumers may benefit if the FDA re-examined labeling requirements for
dietary supplements.
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Background
St. John's wort (Hypericum perforatum), used most com-
monly for depression, is one of the top selling and best
researched herbs used in the USA [1-3]. It is also popular
in Canada and many countries in Europe – including Ger-
many, where it is used more frequently than selective sero-
tonin reuptake inhibitors (SSRIs) [4,5]. In addition to St.
John's wort's (SJW) primary use in depression, there is
increasing interest in research for it in related mental con-
ditions such as obsessive compulsive disorders and social
phobia [6]. While conflicting evidence exists about its effi-
cacy, SJW has demonstrated its most positive results in
mild-to-moderate depression with some success seen in
treating major depression [6,7]. Hypericin and hyperforin
are the components of SJW to which its antidepressant
activity is most commonly ascribed. However, most clini-
cal trials have used SJW extracts standardized to 0.3%
hypericin content with a dose of 300 mg three times a day,
although other dosing regimens have been used [8]. SJW
is believed to exert its antidepressant action by activating
the serotonergic, noradrenergic, and dopaminergic sys-
tems and by activating gamma-aminobutyric acid (GABA)
and glutamic acid receptors in the brain [9,10]. Since SJW
is a pharmacologically active agent, it also is responsible
for adverse reactions and has been associated with multi-
ple potentially serious and clinically relevant drug interac-
tions. Concurrent use of SJW has been implicated in
decreasing plasma levels of cyclosporine A resulting in
organ rejection in transplant patients [11,12]. In HIV
patients, it has decreased plasma levels of indinavir result-
ing in failure of antiretroviral therapy [13]. Women taking
SJW and oral contraceptives could experience a decrease
in efficacy resulting in an increased number of break-
through bleeding events and unplanned pregnancies [14].
Concomitant use of SJW with warfarin has been associ-
ated with decreased anticoagulation properties resulting
in unstable or decreased International Normalized Ratio
(INR) values and is reportedly responsible for decreased
plasma levels of digoxin [15]. Use of SJW is also associated
with the induction of mania or hypomania in patients suf-
fering with bipolar disorder [16]. It has been postulated
that the drug interactions observed with the co-adminis-
tration of SJW and prescription medication such as those
described above are mediated by different mechanisms.
Most of these interactions are consistent with the induc-
tion of cytochrome P450 3A4 enzyme. Further studies
indicate that other likely mechanisms of SJW drug-herb
interactions exist, including enhanced expression and
drug efflux activity of P-glycoprotein/MDR1 [12,17] and
activation of pregnane X [18,19]. Additionally, use of SJW
has been associated with reversible photosensitivity caus-
ing erythematous skin lesions after sun exposure [10].
Despite a fairly well-defined literature and an increase in
educational initiatives, there is still a considerable lack of
knowledge about clinically relevant safety issues associ-
ated with herbs such as St. John's wort among healthcare
professionals (HCPs) [20-23] and employees at health
food stores [24,25] where these products are often pur-
chased. Moreover, many consumers still mistakenly per-
ceive that the use of herbal supplements, also called
"natural remedies", carry little to no risk [26,27]. In addi-
tion to general evaluations of herbal knowledge among
HCPs, knowledge specific to SJW has also been assessed.
One study of physicians revealed that those surveyed were
unaware of interactions involving SJW including: SJW-
warfarin (56%), SJW-digoxin (68%), and SJW-OCP
(68%) [28]. Similarly, a study of community pharmacists
found that 48% were unaware of the interaction between
SJW and cyclosporine, and 32% had not heard of the SJW-
OCP interaction [4].
Since 1994, dietary supplements (i.e. herbs, nutraceuti-
cals, botanicals) have been regulated under the Dietary
Supplement Health and Education Act (DSHEA) in the
USA [29]. Under DSHEA, manufacturers are not required
to provide data demonstrating safety and efficacy of a die-
tary product as long as it was present in the marketplace
prior to the introduction of the legislation. As such, the
Food and Drug Administration (FDA) can only intervene
if a dietary supplement is proven unsafe after it has
already reached consumers. Even then, the onus is on the
FDA to demonstrate that the product is unsafe, rather than
on the manufacturer to produce evidence of its safety.
Dietary supplement manufacturers in the USA also
include or omit safety information on product labels at
their own discretion. The lack of clinically pertinent infor-
mation displayed on the label of natural health products
has recently been addressed in countries such as Canada
where 71% of the population reports using natural prod-
ucts [4]. The new Canadian regulatory measures now
require more specific information to be included on
labels for natural health products including potential drug
interactions and adverse effects [30]. The benefits of
including clinically relevant safety information on dietary
supplement product labels was demonstrated in a recent
study by Sarino et al [14]. Inclusion of drug interaction
information on product labels was associated with a lower
incidence of inappropriate advice dispensed about SJW
products by both pharmacists and health store clerks.
Based on these findings, more comprehensive safety
warnings on the labeling of SJW products may be posi-
tively associated with improved quality of counseling by
pharmacists and advice from health store clerks. This
would help improve patient safety by increasing the like-
lihood of an intervention before an adverse event occurs.
The purpose of this study was to evaluate clinically rele-
vant safety information included on labeling in a nation-
ally representative sample of SJW products in the USA.BMC Complementary and Alternative Medicine 2008, 8:42 http://www.biomedcentral.com/1472-6882/8/42
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Methods
Evaluation Criteria
An exhaustive search was conducted of the primary litera-
ture using secondary databases including MEDLINE,
EMBASE, IPA, MANTIS, and AltHealthWatch for evidence
of safety issues involving SJW. Tertiary resources such as
AltmedDex, Facts & Comparisons Review of Natural Prod-
ucts, Lexi-Natural, Natural Medicines Comprehensive
Database, and Natural Standard were also reviewed.
Safety issues were classified as one of four categories: 1)
SJW – drug interactions, 2) SJW – contraindications, 3)
SJW – therapeutic duplication, and 4) SJW – general. Con-
sideration was given to those safety issues which were doc-
umented based on level of evidence, likelihood of
exposure, and/or those that were theoretical or mechanis-
tic in nature but presented the potential for serious risk.
SJW label evaluation criteria were finalized and are listed
in Additional file 1. Additional safety information from
the label was recorded for all products.
Compilation of products
Sources for compiling the list of SJW products included:
Whole Foods Source Book, Natural Standard, Natural
Medicines Comprehensive Database, ConsumerLab.com,
and Amazon.com. The top 20 retail pharmacy companies,
by pharmacy sales, were also searched for store brand SJW
products. SJW products were identified and then com-
piled into a master list on an Excel spreadsheet. Field
headings of the spreadsheet included: manufacturer,
product, dosage, constituents, uniform resource locator
(URL), and miscellaneous notes along with those head-
ings from Additional file 1.
Only those SJW products produced as a single-ingredient
entity (i.e. no combination products with other herbs)
and commercially available in the USA were eligible for
inclusion. Oral formulations including tablets, capsules,
and caplets were included. SJW products available as
creams, liquids, oils, sprays, teas, and tinctures were
excluded. Homeopathic preparations of SJW were also
excluded. Manufacturers with multiple single-ingredient
SJW products were limited to one representative product.
If multiple products in one line existed, the SJW product
containing a dose of 300 mg was selected as the default
product. If no 300 mg version was available, the next clos-
est dose was selected as that manufacturer's representa-
tive. Products originating from the U.K. and Canada that
were priced in pounds or Canadian dollars, or labeled
according to requirements in their respective country,
were also excluded.
Evaluation process
Guidelines were established with one author performing
evaluations and another rechecking a subset for quality
assurance. For example, credit was given in either case if
the label recommended consulting a "healthcare profes-
sional" or named a specific type of practitioner (e.g. phy-
sician, pharmacist, etc.). This was not the case for related
but non-specific label warnings (e.g. in drug interactions
category, a generic warning about taking with "prescrip-
tion drugs" did not earn credit for the specific warnings for
drugs or classes that were being assessed). Credit was
given for a drug interaction if either the drug class or spe-
cific drug was named (e.g. if the label mentioned warfarin
or Coumadin® or 'blood thinners' it was given credit for
the SJW-warfarin interaction). Only external product labe-
ling was considered for this evaluation.
Results
St. John's wort products
Seventy-four products were identified as available for pur-
chase online, by phone, or at local retailers that met crite-
ria. No product provided all 8 label safety indicators.
However, the most complete labeling information was
observed for three (4.1%) of the products. Each of those
three provided information on 7 of the 8 safety criteria –
including all of the drug-herb interactions. Four products
provided no safety information whatsoever. The percent-
ages of products with label information including the
respective safety issues were as follows: SJW-HIV medica-
tions (8.1%), SJW-immunosupressants (5.4%), SJW-oral
contraceptives (OCPs) (8.1%), SJW-warfarin (5.4%),
bipolar (1.4%), antidepressants (23.0%), phototoxicity
(51.4%), and consult HCP (87.8%). Full results of the
clinically relevant safety information from each product
label are provided in Additional file 1. Other safety-
related information (recorded in the notes field of the
Excel spreadsheet) that appeared most frequently
included warnings about pregnancy (74.3%), lactation
(64.9%), to discontinue if an adverse reaction occurred
(23.0%), and that it was not for use in patients less than
18 years old (13.5%). Additional safety-related informa-
tion noted on SJW labels were warnings about: discontin-
uing two weeks prior to surgery, allergies to ragweed/
daisy-like flowers, avoiding tyramine-containing foods,
and use with severe kidney disease, liver disease, or Par-
kinson's. Specific side effects were also mentioned includ-
ing: anxiety, dizziness, drowsiness, gastrointestinal,
insomnia, restlessness, tiredness, and vivid dreams.
The average number of safety issues included on a product
label was 1.91 (range 0–8) for 23.9% completeness of the
eight criteria determined a priori. Additionally, of the four
safety issues catalogued after the evaluation, the average
label score was 1.76 (44.0%). A combination of the eight
pre-specified and four additional safety issues on labels
had an average score of 3.66 (range 0–12) for 30.5% com-
pleteness.BMC Complementary and Alternative Medicine 2008, 8:42 http://www.biomedcentral.com/1472-6882/8/42
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Discussion
It is a promising finding that the vast majority of SJW
products included some type of prompt for consumers to
consult a HCP in conjunction with taking the herb. How-
ever, the effectiveness of this prompt is contingent upon
the HCP being knowledgeable about the requisite safety
issues. Unfortunately, studies thus far have indicated that
this necessary knowledge is not universally possessed
[4,28]. Additionally, specificity of label safety informa-
tion, rather than a blanket warning, has been more closely
tied to making a positive impact on the quality of advice
dispensed about these products [14]. This provision of
specific, clinically relevant safety information on the label
is where the SJW products performed the most poorly in
this study. Since no warning within the drug interaction
category even reached 10% inclusion on all SJW labels,
the potential for negative impact on patient safety
remains. If HCPs and health store clerks are uninformed
about these interactions and have even disavowed knowl-
edge of their existence in some cases [14], how many pre-
ventable adverse events are occurring where incomplete
product safety labeling is a contributing factor? This could
be particularly problematic as the initial point of contact
for a consumer interested in purchasing a dietary supple-
ment is often a pharmacist or health store clerk. Addition-
ally, health food store personnel have even been
identified as a source of information ranking higher than
physicians, dietitians, and other HCPs when consumers
consider using herbal products [31].
Complicating matters further is that SJW and its compo-
nents have been studied in treating HIV due to its antiret-
roviral properties in vitro [32]. While this is likely a minor
issue as the compound was administered intravenously
and not found efficacious, the possibility exists HIV
patients will take SJW to treat their HIV/AIDS which could
compromise their conventional cocktails/therapy. This
possibility is heightened by the fact that some SJW prod-
ucts are labeled with this type of indication (e.g. "has been
skillfully crafted to promote antiviral/antibacterial prop-
erties..." is one such statement found on the study product
labels). Alarmingly, information and recommendations
of SJW to treat HIV persist on the Internet in both scien-
tific and non-scientific sources that could send mixed
messages to consumers and health care professionals
[33,34].
While the majority of products performed below expecta-
tions, the labeling of three products did stand out posi-
tively. SJW products by Douglas Labs, Nature Made, and
New Chapter all included each of the four drug interac-
tion alerts and 7 of the 8 safety issues overall. Since this is
an industry largely driven by self-regulation, it is of inter-
est why these three outliers contained the breadth of
safety issues that the other products did not include on
their labels. Since Douglas Labs specifically targets HCPs
rather than consumers with their product lines, they may
be more in-tune with the clinically oriented needs of phy-
sicians and pharmacists. They also consult with their sci-
entific advisory board and insurance carrier to help
develop label recommendations. Nature Made has part-
nered with the American Botanical Council (ABC) in
order to determine which safety information to include
and uses an accordion-style label to help display the rele-
vant information. Finally, New Chapter relies on their in-
house scientific counsel and review process along with
direction from the American Herbal Products Association
(AHPA) to generate a more complete label. All three
approaches have been successful in that they have all pro-
duced a label far more complete than the industry average
in addressing clinically relevant safety issues.
The possibility exists that selectively targeting products
such as these top performers for recommendations or
inclusion in product inventories at pharmacies, health
stores and physician groups could result in better
informed consumers, employees, and HCPs and ulti-
mately improves the quality of advice dispensed. This, of
course, would be a short-term solution as different market
forces could act to interfere with this line of action. The
absence of relevant safety warnings on SJW product labels
resembles results from the assessment of aspirin-related
safety warnings on white willow bark product labels,
which demonstrated a similar dearth of safety informa-
tion [35]. In that case, the lack of aspirin-warnings on a
product label likely contributed to a negative clinical out-
come and an emergency department admission [36]. The
poor label performances seen in this study should herald
potential dangers to the Food and Drug Administration
(FDA), HCPs, manufacturers, and consumers. The self-
regulating nature of the dietary supplement industry
under the auspices of DSHEA, and minimal FDA involve-
ment, has resulted in a very broad range of safety warnings
included on the product labels of herbal products. More
unified and comprehensive regulatory measures for die-
tary supplement labels could yield safer use of these sup-
plements and result in more complete information
available to consumers, HCPs, and health store personnel.
Limitations
The sample of products used in this study was limited to
those commercially available in the USA, thus results can-
not be extrapolated to products in other countries. Addi-
tionally, not every interaction, side effect, and safety-
related issue that has been documented or proposed
regarding SJW was assessed in this study. The inclusion or
exclusion of certain safety issues could have affected the
scores of different SJW products. However, given that
three products had labels that were so much more com-
plete than the rest of the products, any changes in scoresBMC Complementary and Alternative Medicine 2008, 8:42 http://www.biomedcentral.com/1472-6882/8/42
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would likely have been minor and not have substantially
affected the study results. Finally, as this was not an inter-
ventional study, it is uncertain exactly how the use of
products with a high percentage of safety issues on the
labels would translate into actual patient benefit and
adverse event prevention.
Conclusion
The vast majority of SJW products fail to adequately
address clinically relevant safety issues on their labeling. A
small number of products do provide an acceptable
amount of information on drug-herb interactions and
other safety issues which could enhance the quality of
advice and counseling by HCPs and health store clerks.
Both HCPs and consumers may ultimately realize the
greatest benefit if the FDA were to re-examine labeling
requirements of dietary supplements.
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